Journal: Respiratory Research

Article Title: Monoclonal enolase-1 blocking antibody ameliorates pulmonary inflammation and fibrosis

doi: 10.1186/s12931-023-02583-3

Figure Lengend Snippet: ENO1 is upregulated in fibrotic lungs from human and bleomycin-treated mice. (A, B) IHC staining of ENO1 was performed in commercially available human normal (n = 3) and fibrosis (n = 3) lung FFPE sections. (C, D) After intratracheal injection of bleomycin (BLM, 3 mg/kg) (n = 7) or PBS vehicle control (Sham) (n = 4), the mouse lungs were harvested on day 21 for preparation of FFPE sections and subjected to IHC staining of ENO1. Representative pictures (A, C) and quantitative results of ENO1-stained positive areas were shown (B, D) . After intratracheal injection of bleomycin (BLM, 3 mg/kg) (n = 4) or PBS vehicle control (Sham) (n = 4), the mouse lungs were harvested on day 21 for preparation of lysates and subjected to Western blotting for ENO1 (E) and the relative densitometry was shown below the representative blot after GAPDH normalization. Cropped blots were shown, and supplementary Fig. presented the full-length blots. Quantitative results were shown by fold change after bleomycin treatment (F) . Scale bar, 100 µM. * P < 0.05, ** P < 0.01. (A, B) One experiment was performed and each picture or data point was from one human subject. (C-F) Data were representative for two independent experiments. Each picture, data point, or protein band was from one mouse except ( F ) was shown as mean ± SD

Article Snippet: Three human fibrotic lung FFPE sections (#CS701530, #CS702702, #CS703355) were obtained from OriGene (Rockville, MD, USA).

Techniques: Immunohistochemistry, Injection, Control, Staining, Western Blot

Journal: Respiratory Research

Article Title: Monoclonal enolase-1 blocking antibody ameliorates pulmonary inflammation and fibrosis

doi: 10.1186/s12931-023-02583-3

Figure Lengend Snippet: Blocking ENO1 ameliorates lung fibrosis in bleomycin-treated mice. After intratracheal injection of 3 mg/kg bleomycin (BLM) (day 0), mice were treated with ENO1 Ab HL217 (10 mg/kg) intravenously on a 6-day interval from day 1. Mouse lungs were harvested on day 14 or 21 for preparation of FFPE sections and subjected to H&E staining (A) and Masson’s trichrome staining (B) . Representative pictures on day 21 (A, B) and quantitative results of Ashcroft score on day 21 (C) and inflammation score on day 14 (D) were shown. Body weight change (E) , ratio of lung weight versus body weight (F) , collagen content of the lungs (G) , and levels of TGF-β in BALF (H) were shown. Scale bar, 100 µM. * P < 0.05, ** P < 0.01, *** P < 0.001. Data were representative for two independent experiments. Each picture or data point was from one mouse except (E) was shown as mean ± SEM

Article Snippet: Three human fibrotic lung FFPE sections (#CS701530, #CS702702, #CS703355) were obtained from OriGene (Rockville, MD, USA).

Techniques: Blocking Assay, Injection, Staining

Journal: Cancer Science

Article Title: Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10

doi: 10.1111/j.1349-7006.2007.00701.x

Figure Lengend Snippet: Immunohistochemical staining analyses of synovial sarcoma and normal human tissue sections using MAb 92‐13; (a,b) synovial sarcoma tissue sections (c) colon, (d) heart, (e) lung, (f) liver, (g) kidney and (h) placenta. Original magnification ×100. Bar, 50 µm.

Article Snippet: For immunohistochemical staining analysis, 4‐µm sections of paraffin‐embedded normal adult human tissues (lung, heart, liver, kidney, colon and placenta) (BioChain, Hayward, CA, USA) and surgical synovial sarcoma specimens were deparaffinized and processed for antigen retrieval in Target Retrieval Solution (pH 9) (DAKO Cytomation, Carpinteria, CA, USA) at 125°C for 30 s. After treatment with peroxidase blocking reagent (DAKO Cytomation) for 10 min, followed by treatment with protein blocking serum‐free (DAKO Cytomation) for 30 min, slides were incubated with 10 µg/mL MAb 92‐13.

Techniques: Immunohistochemical staining, Staining